SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express bullish sentiment and encourage adding it to watchlists. Conversations revolve around community strength and shared conviction, particularly within the meme space. The tags $SLAP, $DOG, and $RAGE are frequently used alongside $WAGMI.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as conversations highlight its strong community, even during market dips, with the community referring to itself as the "$DOG Army." There is growing excitement around the potential integration with Zap, and how it could affect exposure. Discussion also centers around $DOG's relationship with Bitcoin and the Rune revolution.

EQT Corp. is a natural gas production company, which engages in the provision of supply, transmission, and distribution of natural gas. The company was founded in 1888 and is headquartered in Pittsburgh, PA.

EQT Corp

EQT is trending amid discussions about its potential to capitalize on rising natural gas demand, particularly with the approaching winter season and increased flows to LNG export plants. Community members are analyzing technical indicators and options activity, while also debating the impact of potential policy changes and market dynamics on the stock's performance. Some caution is present due to a recent analyst downgrade, offset by bullish sentiment related to long-term growth and AI-driven energy needs.

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Mimedx Group Inc

Mimedx Group is trending due to discussions around the potential impact of new CMS reimbursement rules for skin substitute products and a possible shift in market dynamics. The community is weighing the company's competitive advantages against concerns about future revenue and earnings, especially in light of analyst reports and guidance. Some investors express frustration with the company's leadership and advocate for a potential sale.

Cantor Equity Partners, Inc. is a blank check company, which engages in the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 11, 2020 and is headquartered in New York, NY.

Cantor Equity Partners Inc. - Ordinary Shares - Class A

Cantor Equity Partners Inc

Cantor Equity Partners ($CEP) is trending due to community excitement surrounding its impending merger with Twenty One Capital ($XXI), a Bitcoin treasury company, and the potential ticker change. Discussions revolve around the merger's timeline, the value of CEP post-merger, and the influence of key figures like Jack Mallers and Tether. Some traders express skepticism while others anticipate a significant price surge upon completion of the merger.

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.

Cytek BioSciences Inc

Recent analyst ratings adjustments from Piper Sandler and Goldman Sachs, along with community discussion around undervaluation, are contributing to $CTKB's increased visibility. Community members are also highlighting the company's technology and potential within the life science tools sector, viewing it as a hidden gem. Expanded risk factors and insider selling may also be influencing investor sentiment.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid community discussion around the release of Epstein files and Trump's alleged connections. Reactions are mixed, with some users defending Trump and others questioning his motives for potentially blocking the release. Broader discussions involve political divides and the stock's valuation relative to its fundamentals.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as the Winklevoss twins are reportedly accumulating ZEC through Cypherpunk Technologies, sparking speculation about a potential ZEC ETF and drawing comparisons to MicroStrategy's Bitcoin holdings. Community members are weighing the potential for further gains against concerns of a possible correction, with some highlighting Zcash's focus on privacy as a key differentiator in the crypto space. The discussion includes various price predictions and trading strategies, with attention to the interplay between ZEC and Cypherpunk Technologies' stock.

DoubleDown Interactive Co., Ltd. engages in the gaming entertainment business. It operates through the Gaming and iGaming business divisions. The Gaming business division develops and publishes social casinos and casual games. The iGaming business division refers to development and operation of license-based online casinos. The company was founded in December 2007 and is headquartered in Seoul, South Korea.

DoubleDown Interactive Co Ltd - ADR

DoubleDown Interactive Co.

DoubleDown Interactive (DDI) is trending as investors analyze its balance sheet, particularly its cash reserves and earnings, with some suggesting it's undervalued. Community members are discussing potential catalysts such as acquisitions and the impact of South Korean corporate governance reforms. Some are also awaiting news regarding potential dividends or share repurchase programs, while also noting a recent analyst upgrade.

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Edwards Lifesciences Corp

Edwards Lifesciences ($EW) is trending amid analyst target adjustments and anticipation for upcoming Q3 earnings, with key segments like TAVR and TMTT in focus. Community members are closely watching resistance levels and prior market memory areas, while also debating the stock's overall direction and potential for a breakout. New clinical trial data has also emerged, impacting investor sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Scholar Rock Holding Stock Climbing Today?

Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.read more...

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did Scholar Rock Soar 26% Today?

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year. 

Equity

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe...

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the Company) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee...

Scholar Rock (SRRK) to Release Earnings on Friday

Scholar Rock (NASDAQ:SRRK) will be releasing its Q3 2025 earnings before the market opens on Friday, November 14. (View Earnings Report at...

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November 14, 2025, before the financial markets open. Following the release of the...

Scholar Rock (NASDAQ: SRRK; the Company), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and...

A Canaccord analyst on Monday highlighted the risks associated with the U.S. Food and Drug Administration’s ‘Official Action Indicated’ designation on Catalent Indiana LLC, a third-party fill-finish facility.Novo Nordisk's (NVO) update that the FDA has classified Catalent Indiana LLC as "Official Action Indicated" raises the risk of further delay for Regeneron’s (REGN) Eylea HD prefilled syringes, as they are produced at the same site, the analyst noted. Catalent Indiana was acquired by Novo Nordisk (NVO) in December.Notably, Regeneron had <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">said</a> in August that the FDA extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions until the fourth quarter, owing to issues identified at the fill-finish facility.Regeneron is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/scholar-rock-in-spotlight-after-fda-refuses-to-approve-muscular-atrophy-treatment/chDhUSIR35Z">refused</a> to approve Scholar Rock’s (SRRK) Apitegromab drug for the treatment of patients with spinal muscular atrophy over concerns identified during the inspection of Catalent Indiana's facility.Breaches at Catalent Indiana’s facility have been classified as "Official Action Indicated," Scholar Rock said in a statement. The serious designation means regulatory and/or administrative actions are recommended to resolve the concerns identified.Scholar Rock said that it continues to work closely with Novo and has requested a meeting with the FDA to discuss the next steps for resubmitting its Apitegromab drug application.While REGN shares traded 2% lower at the time of writing, <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> fell 12%. While retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, sentiment around SRRK rose from ‘neutral’ to ‘bullish’ territory.<figure class="image"><img style="aspect-ratio:620/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_1_20_48_PM_png_df71d2ade1.webp" alt="REGN's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="620" height="61"><figcaption>REGN's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:623/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_1_21_27_PM_png_5e9ad0811c.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="623" height="63"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure>SRRK stock has dropped about 20% this year, while REGN lost 22%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-approves-changed-recommendations-for-use-of-abbvie-rinvoq/ch6SFlFR3lG">AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Are Regeneron And Scholar Rock Shares Falling On Monday?

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 

Shares of Scholar Rock (SRRK) rose about 2% on Tuesday morning after falling 12% in the pre-market session after the U.S. Food and Drug Administration refused to approve its Apitegromab drug for the treatment of patients with spinal muscular atrophy (SMA).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/fda-issues-complete-response-letter-crl-apitegromab-treatment">stated</a> that the FDA raised concerns identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility. The agency did not make any observations specific to its drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data, the company said.Catalent Indiana was acquired by Danish drugmaker Novo Nordisk (NVO) in December. The facility submitted a response in early August 2025 to address the observations noted by the FDA and has continued to take corrective actions, the company said.Scholar Rock said it will resubmit its application for Apitegromab once Catalent Indiana’s issues with the FDA are resolved. The company stated that it believes the FDA will be able to act expeditiously on the application once the manufacturing issues have been resolved. “We are continuing to work closely with Catalent Indiana on the FDA’s manufacturing observations so that we can resubmit the apitegromab BLA (application) as soon as possible,” said CEO David L Hallal.Scholar Rock has also submitted Apitegromab for approval by the European Medicines Agency, and a decision is anticipated near mid-2026, the company said. It expects a European launch for the drug in the second half of 2026, starting with Germany.Scholar Rock believes Apitegromab may lead to a clinically meaningful improvement in motor function in patients with Spinal Muscular Atrophy (SMA), a rare, severe, genetic neuromuscular disease characterized by motor function decline.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_9_42_28_AM_png_308ee0f990.webp" alt="SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>Scholar Rock is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, Regeneron (REGN) <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">announced</a> that the FDA had extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions due to issues identified at the facility. &nbsp;SRRK stock is down 23% this year but up approximately 282% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amneal-pharma-stock-rises-on-fda-approval-for-generic-version-of-abbvie-eyedrops/chDhHHIR35Q">Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock Holding Corp

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$37.28
Prev Close	$30.07
Open	$34.98
Dividend Yield	0.00%
50-Day Moving Average	$32.45
Beta	1.16
Avg. Volume	3.06M
PE Ratio	-12.40

52-Week High	$46.98
52-Week Low	$22.71
Market Capitalization	$3.6B
EPS (Annual)	-$2.47
Price to Book	15.39
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SRRK
Scholar Rock Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRRK News

SRRKScholar Rock Holding Corp